Even in their intended disease subset, Epithelial Growth Factor Receptor tyrosine kinase inhibitors leave behind residual disease eventually resulting in acquired resistance. Our study indicates that this process is driven by Aurora Kinase A. Inhibition of Aurora signaling may prevent the onset of acquired resistance and counteract progressive disease.
Keywords: Aurora kinase; EGFR; acquired resistance; and chromosomal instability; apoptosis; lung cancer; tumor evolution.